Home › Funds › Equitable › EQ/AB Small Cap Growth Portfolio
Fund family: Equitable · Filed by EQ ADVISORS TRUST (CIK 1027263) · SEC series S000009056
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 725 with, 4 against, 0 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 4 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Equitable’s manager page (393,894 ballot items across 72 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Equitable | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 88.5% | 703 | 92.5% | 339,726 |
| Backed environmental and social shareholder proposals at US companies | n/a | 0 | 9.6% | 3,486 |
Each ballot item this fund voted is set against the votes of the other Equitable funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Equitable funds on 23 items (3.4% of the 676 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Equitable funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Lumexa Imaging Holdings, Inc. | 2026-06-10 | To elect three Class I directors to the Board of Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Brian Regan | For | WITHHOLD — 5 of 5 Equitable funds | For | — |
| Dianthus Therapeutics, Inc. | 2026-05-21 | To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorge | Withhold | FOR — 7 of 8 Equitable funds | Against | Passed (calculated), 80.6% support |
| Erasca, Inc. | 2026-06-26 | To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Alexander W. Casdin | Withhold | FOR — 5 of 6 Equitable funds | Against | Elected, 88.0% support |
| BridgeBio Pharma, Inc. | 2026-06-22 | To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly ele | Withhold | FOR — 5 of 8 Equitable funds | Against | Passed (calculated), 97.3% support |
| BridgeBio Pharma, Inc. | 2026-06-22 | To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly ele | Withhold | FOR — 5 of 8 Equitable funds | Against | Passed (calculated), 95.0% support |
| BridgeBio Pharma, Inc. | 2026-06-22 | To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly ele | Withhold | FOR — 5 of 8 Equitable funds | Against | Passed (calculated), 80.1% support |
| Kymera Therapeutics, Inc. | 2026-06-24 | To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Elena Ridloff, CFA | Withhold | FOR — 5 of 8 Equitable funds | Against | Passed (calculated), 93.6% support |
| Granite Construction Incorporated | 2026-06-04 | Election of Directors: Carlos M. Hernandez | Against | FOR — 5 of 8 Equitable funds | Against | Passed (calculated), 96.1% support |
| Granite Construction Incorporated | 2026-06-04 | Election of Directors: Celeste B. Mastin | Against | FOR — 5 of 8 Equitable funds | Against | Passed (calculated), 94.6% support |
| Denali Therapeutics Inc. | 2026-06-03 | ELECTION OF DIRECTORS: David Schenkein, M.D. | Withhold | FOR — 5 of 8 Equitable funds | Against | Elected, 73.5% support |
| Nuvalent, Inc. | 2026-06-16 | Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D. | Withhold | FOR — 5 of 8 Equitable funds | Against | Elected, 81.5% support |
| Generac Holdings Inc. | 2026-06-11 | Election of Class II Directors: Bennett J. Morgan | Against | FOR — 8 of 15 Equitable funds | Against | Passed (calculated), 83.3% support |
| Relay Therapeutics, Inc. | 2026-06-09 | To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Claire Mazumdar, Ph.D. | Withhold | FOR — 4 of 6 Equitable funds | Against | Elected, 83.5% support |
| Relay Therapeutics, Inc. | 2026-06-09 | To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Douglas S. Ingram | Withhold | FOR — 4 of 6 Equitable funds | Against | Elected, 82.2% support |
| Vera Therapeutics, Inc. | 2026-05-21 | To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Michael M. Morrissey, Ph.D. | Withhold | FOR — 4 of 6 Equitable funds | Against | Elected, 76.6% support |
| Vera Therapeutics, Inc. | 2026-05-21 | To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Patrick G. Enright | Withhold | FOR — 4 of 6 Equitable funds | Against | Elected, 92.5% support |
| Ocular Therapeutix, Inc. | 2026-06-10 | To elect two Class III directors, each to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Merilee Raines | Withhold | FOR — 4 of 6 Equitable funds | Against | Elected, 86.9% support |
| DigitalOcean Holdings, Inc. | 2026-06-15 | Election of Class II Directors: Warren Adelman | Withhold | FOR — 5 of 9 Equitable funds | Against | Passed (calculated), 79.8% support |
| Guardant Health, Inc. | 2026-06-17 | Election of Class II Directors: Ian Clark | Withhold | FOR — 4 of 7 Equitable funds | Against | Elected, 65.0% support |
| Guardant Health, Inc. | 2026-06-17 | Election of Class II Directors: Manuel Hidalgo Medina | Withhold | FOR — 4 of 7 Equitable funds | Against | Elected, 75.5% support |
| Glaukos Corporation | 2026-05-28 | Election of Directors: Aimee S. Weisner | Withhold | FOR — 4 of 7 Equitable funds | Against | Passed (calculated), 95.0% support |
| Glaukos Corporation | 2026-05-28 | Election of Directors: Denice M. Torres | Withhold | FOR — 4 of 7 Equitable funds | Against | Passed (calculated), 78.5% support |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Badreddin Edris, Ph.D. | For | WITHHOLD — 3 of 5 Equitable funds | For | Elected, 70.3% support |
Download all 23 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 85.7% of this fund’s 729 such votes could be given a sector; the other 104 (14.3%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 155 | 0 | 0.0% |
| Industrials | 135 | 2 | 1.5% |
| Technology | 119 | 0 | 0.0% |
| Consumer Discretionary | 99 | 1 | 1.0% |
| Finance | 59 | 0 | 0.0% |
| Consumer Staples | 26 | 0 | 0.0% |
| Energy | 18 | 0 | 0.0% |
| Utilities | 10 | 1 | 10.0% |
| Basic Materials | 4 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 484 | 0 |
| Audit-related | 93 | 0 |
| Say-on-Pay | 82 | 0 |
| Compensation | 29 | 0 |
| Corporate Governance | 23 | 4 |
| Capital Structure | 19 | 0 |
| Extraordinary Transactions | 5 | 0 |
| Shareholder Rights and Defenses | 2 | 0 |
| Other | 1 | 0 |
| Other Social Issues | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Glaukos Corporation | May 28, 2026 | $29M | 4 | 0 |
| Coherent Corp. | November 13, 2025 | $28M | 7 | 0 |
| Comfort Systems USA, Inc. | May 18, 2026 | $25M | 12 | 0 |
| Guardant Health, Inc. | June 17, 2026 | $22M | 5 | 0 |
| BrightSpring Health Services, Inc. | May 21, 2026 | $21M | 5 | 0 |
| Lattice Semiconductor Corporation | May 1, 2026 | $21M | 10 | 0 |
| Bloom Energy Corporation | May 21, 2026 | $21M | 8 | 0 |
| Rocket Lab Corporation | May 20, 2026 | $19M | 4 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 7, 2026 | Murphy USA Inc. | Stockholder Proposal - Give Shareholders the Ability to Call for a Special Shareholder Meeting. Shareholder proposal | For | Against |
| May 11, 2026 | MKS Inc. | A shareholder proposal to reduce the threshold percentage of shareholders required to call a special meeting of shareholders from 40% to 10%, if properly presented at the meeting. Shareholder proposal | For | Against |
| May 5, 2026 | Albemarle Corporation | Shareholder Proposal regarding shareholders ability to call for a special shareholder meeting. Shareholder proposal | For | Against |
| May 5, 2026 | DT Midstream, Inc. | Stockholder Proposal on Shareholder Right to Act by Written Consent. Shareholder proposal | For | Against |
739 ballot items at 88 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, EQ/AB Small Cap Growth Portfolio voted at 88 shareholder meetings of 88 companies, on 739 ballot items in all. Where management made a recommendation, the fund followed it on 99.5% of the items and voted against it 4 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 4 shareholder proposals. It voted FOR the board's own proposals less often than Equitable's funds as a whole (88.5% against 92.5%). It voted differently from most Equitable funds on 23 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Equitable’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.